Alexza to Report 2014 First Quarter Financial Results on Monday, May 5, 2014

 Alexza to Report 2014 First Quarter Financial Results on Monday, May 5, 2014

PR Newswire

MOUNTAIN VIEW, Calif., April 16, 2014

MOUNTAIN VIEW, Calif., April 16, 2014 /PRNewswire/ -- Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended March 31,
2014 on Monday, May 5, 2014, following the close of the U.S. financial
markets. The Company will also host an investor conference call and live
webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to
provide a company update and discuss the financial results.

Alexza Pharmaceuticals.

To access the webcast via the Internet, go to, under the
"Investor Relations" link. Please log onto the webcast prior to the start of
the call to ensure time for any software downloads that may be required to
participate in the webcast.

To access the live conference call, dial 888-680-0890 or +1-617-213-4857
(international). The reference number to enter the call is 42668133.
Interested parties may also pre-register for the call at

A replay of the conference call may be accessed at under the
"Investor Relations" link, or by dialing 888-286-8010 or +1-617-801-6888
(international). The reference number for the replay of the call is
24434341. A replay of the call will be available for 14 days following the

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions. Alexza's products are based on the
Staccato^® system, a hand-held inhaler designed to deliver a drug aerosol to
the deep lung, providing rapid systemic delivery and therapeutic onset, in a
simple, non-invasive manner.

ADASUVE is Alexza's first commercial product. It has been approved for sale
by the U.S. Food and Drug Administration and the European Commission. Teva
Pharmaceuticals USA, Inc. is Alexza's commercial partner for ADASUVE in the
U.S. Grupo Ferrer Internacional, S.A. is Alexza's commercial partner for
ADASUVE in Europe, Latin America and the Commonwealth of Independent States.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,

Safe Harbor Statement
The anticipated news release and conference call will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of 1995,
and should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of Alexza and its
partners, Teva and Ferrer, to effectively and profitably commercialize
ADASUVE, estimated product revenues and royalties associated with the sale of
ADASUVE, the adequacy of the Company's capital to support the Company's
operations, and the Company's ability to raise additional funds and the
potential terms of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect, would cause
its results to differ materially from those expressed or implied by such
forward-looking statements. These and other risks concerning Alexza's business
are described in additional detail in the Company's Annual Report on Form 10-K
for the year ended December 31, 2013 and the Company's other Periodic and
Current Reports filed with the Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made as of this
date, and the Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information, future
events or otherwise.

Logo -

SOURCE Alexza Pharmaceuticals, Inc.

Contact: Thomas B. King, President and CEO, 650.944.7634,,
Mark K. Oki, SVP, Finance and CFO, 650.944.7666,
Press spacebar to pause and continue. Press esc to stop.